Statins decrease mean platelet volume irrespective of cholesterol lowering effect

Basit Öğe Kaydı
dc.authorwosidaksoy, yüksel/ABH-1304-2021
dc.contributor.authorSivri, Nasir
dc.contributor.authorTekin, Gulacan
dc.contributor.authorYalta, Kenan
dc.contributor.authorAksoy, Yuksel
dc.contributor.authorSenen, Kubilay
dc.contributor.authorYetkin, Ertan
dc.date.accessioned2024-06-12T11:15:39Z
dc.date.available2024-06-12T11:15:39Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Recent clinical observations have demonstrated that the beneficial effects of statins are not limited to LDL lowering effect. They have also favourable effects on platelet activation, endothelial function, inflammation, and coagulation cascade. Aim: To investigate the effects of statins on mean platelet volume (MPV) which is a simple measure of platelet activation volume in patients who have been prescribed statins. Atorvastatin and rosuvastatin were also compared in respect to effects on MPV. Methods: One hundred and forty five patients were retrospectively included in the study from the outpatient cardiology clinic. Patients who had been given statin treatment were recruited based on the records. Baseline and 4-8 weeks biochemical analysis and haematological measurements and cardiovascular risk factors were recorded. Results: Both statins significantly decreased the MPV. MPV of patients did not show any significant correlation with lipid parameters. Linear regression analysis revealed that there were no statistically significant associations of D MPV with the Delta LDL-cholesterol (beta coefficient = 0.13; p = 0.24), Delta HDL-cholesterol (beta coefficient = 0.17; p = 0.18) or Delta triglyceride (beta coefficient = -0.11; p = 0.21) after statin treatment. Both statins had comparable effects on lipid parameters at the end of the one month follow up period. Conclusion: Statins significantly reduce MPV irrespective of cholesterol levels, and atorvastatin and rosuvastatin have comparable effects in this regard.en_US
dc.identifier.doi10.5603/KP.2013.0259
dc.identifier.endpage1047en_US
dc.identifier.issn0022-9032
dc.identifier.issn1897-4279
dc.identifier.issue10en_US
dc.identifier.pmid24197585en_US
dc.identifier.scopus2-s2.0-84888242522en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1042en_US
dc.identifier.urihttps://doi.org/10.5603/KP.2013.0259
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24003
dc.identifier.volume71en_US
dc.identifier.wosWOS:000329876300006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofKardiologia Polskaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectStatinen_US
dc.subjectMean Platelet Volumeen_US
dc.subjectPlatelet Activationen_US
dc.subjectCoa Reductase Inhibitorsen_US
dc.subjectAcute Coronary Syndromesen_US
dc.subjectAtorvastatinen_US
dc.subjectExpressionen_US
dc.subjectInterleukin-6en_US
dc.subjectInterventionen_US
dc.subjectInflammationen_US
dc.subjectCoagulationen_US
dc.subjectActivationen_US
dc.subjectImbalanceen_US
dc.titleStatins decrease mean platelet volume irrespective of cholesterol lowering effecten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu